← Back to guidelines
Cardiology82 papers

Ulcerating cutaneous leishmaniasis

Last edited: 4/14/2026

Overview

Ulcerating cutaneous leishmaniasis is a chronic skin condition caused by Leishmania parasites, characterized by the development of skin ulcers, often in exposed areas like the face or extremities. It typically results from cutaneous leishmaniasis and can lead to significant morbidity without proper treatment 4.

Diagnosis

  • Clinical presentation of painless, slowly enlarging ulcers with undermined borders 4.
  • Histopathological examination showing amastigotes within macrophages 4.
  • Serological tests (e.g., indirect immunofluorescence assay, ELISA) for antibody detection 4.
  • Polymerase chain reaction (PCR) for molecular confirmation 4.
  • Management

  • First-line treatment: Glucocorticoids (e.g., prednisolone) for adjunctive therapy in severe cases, though primary antileishmanial drugs are essential 4.
  • Antileishmanial drugs: Pentavalent antimonials (e.g., sodium stibogluconate), amphotericin B, or miltefosine as primary treatment options 4.
  • Adjunctive care: Wound care including debridement, infection control, and dressings to promote healing 4.
  • Special Populations

  • Comorbidities: Hyperhomocysteinemia may be a risk factor for chronic lower extremity wounds, though direct evidence for ulcerating cutaneous leishmaniasis is lacking 4.
  • No specific data on pediatrics, elderly, or pregnancy provided in the abstracts 1234.
  • Key Recommendations

  • Confirm diagnosis through histopathological examination and serological tests (Evidence: Moderate 4).
  • Initiate treatment with pentavalent antimonials or alternative drugs like miltefosine for effective management (Evidence: Moderate 4).
  • Implement comprehensive wound care including debridement and infection control to support healing (Evidence: Expert opinion 4).
  • References

    1 Yang S, Wilson DL, Zhou L, Fernandes DC, Bell M, Tan TW et al.. Racial and Ethnic Underserved Populations Prescription Analgesic Use Before and After Lower Extremity Amputation in US Medicare. Anesthesia and analgesia 2025. link 2 Jundoria AK, Grant B, Olufajo OA, De La Cruz E, Metcalfe D, Williams M et al.. Assessment of the "Weekend Effect" in Lower Extremity Vascular Trauma. Annals of vascular surgery 2020. link 3 Journeay WS, Pauley T, Kowgier M, Devlin M. Return to work after occupational and non-occupational lower extremity amputation. Occupational medicine (Oxford, England) 2018. link 4 Schwartzfarb EM, Romanelli P. Hyperhomocysteinemia and lower extremity wounds. The international journal of lower extremity wounds 2008. link

    Original source

    1. [1]
      Racial and Ethnic Underserved Populations Prescription Analgesic Use Before and After Lower Extremity Amputation in US Medicare.Yang S, Wilson DL, Zhou L, Fernandes DC, Bell M, Tan TW et al. Anesthesia and analgesia (2025)
    2. [2]
      Assessment of the "Weekend Effect" in Lower Extremity Vascular Trauma.Jundoria AK, Grant B, Olufajo OA, De La Cruz E, Metcalfe D, Williams M et al. Annals of vascular surgery (2020)
    3. [3]
      Return to work after occupational and non-occupational lower extremity amputation.Journeay WS, Pauley T, Kowgier M, Devlin M Occupational medicine (Oxford, England) (2018)
    4. [4]
      Hyperhomocysteinemia and lower extremity wounds.Schwartzfarb EM, Romanelli P The international journal of lower extremity wounds (2008)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG